A recent study suggests that people who come off popular weight-loss injections like Wegovy and Mounjaro can put back on lost weight much more quickly than those who halt conventional diet and exercise plans.
Findings released in a prominent health publication shows that while overweight individuals often shed a large proportion of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such treatments must be cognizant of the danger of fast weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass in about a year and a half.
Weighing Treatments
The research, which examined dozens of trials involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Researchers note that individuals who lose weight through dieting typically experience a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Fast Regain
Nutrition scientists propose the mechanism of the injections accounts for the accelerated weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making binge eating a significant risk."
A Chronic Condition?
Health authorities suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who state that the findings "highlight the chronic nature of obesity," similar to managing diseases like high blood pressure.
Patient Testimonies
Users who have discontinued the medication describe a intense return of hunger.
"I experienced something activating and you become starving," recalled one woman.
This difficulty is exacerbated if users have not developed sustainable dietary or behavioural changes during treatment.
Growing Adoption
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent solution and long-term success relies on ongoing behavioural changes.
